{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007616","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.108903+00:00","generated_at":"2026-06-05T17:31:13.765642+00:00","sec_items":["1.01","3.02","3.03","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera closes $8M private placement of convertible preferred shares, warrants for up to $8M more","bullets":["$8.0 million raised from Series B-1 Preferred at $1,000/share; warrants for additional $8.0 million upon milestone achievement and shareholder approval.","Conversion price $0.7074; Series B-1 convertible into up to 9,310,677 common shares; warrants into 11,309,019 shares.","Net proceeds for working capital and development of additional indications for Ameluz (actinic keratosis).","Initial conversion of preferred shares into 2,516,785 common shares, increasing total outstanding to 5,089,413 common shares.","Roth Capital Partners acted as placement agent; Rosalind Advisors led institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007616","json":"https://secwatch.observer/filing/0001493152-24-007616.json","markdown":"https://secwatch.observer/filing/0001493152-24-007616.md","text":"https://secwatch.observer/filing/0001493152-24-007616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T17:31:13.765642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"401b6e5d0cb6b779237e895ba5848f2c1979e3c7","claim":"Biofrontera Inc.: Filed Certificate of Designation for Series B Preferred Stock, establishing rights, preferences, and limitations of three new series of preferred stock (effective 2024-02-20).","evidence_excerpt":"on February 20, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 6,586 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock, 6,586 shares as Series B-2 Preferred Stock and 8,000 shares as Series B-3 Convertible Preferred Stock","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-20"}],"fact_type":"governance_change"},{"claim_id":"1b1091fb4f2782db30ea4af26ad6d5e1a3cd80a1","claim":"Biofrontera Inc. entered into Securities Purchase Agreement with accredited investors (Preferred Investors) valued at $8,000,000 (effective 2024-02-19).","evidence_excerpt":"On February 19, 2024, the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Preferred Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 6,586 shares of Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), and (iii) warrants (the “ Preferred Warrant ”) to purchase shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-3 Preferred Stock ”) for an aggregate offering price of $8.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm","confidence":0.97,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors (Preferred Investors)"},{"label":"Value","value":"$8,000,000"},{"label":"Effective","value":"2024-02-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}